Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma-Reference-Cited by-同舟云学术

Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma

Published:2008-04 Issue:6 Volume:44 Page:876-884
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bersani Francesca,Taulli Riccardo,Accornero Paolo,Morotti Alessandro,Miretti Silvia,Crepaldi Tiziana,Ponzetto Carola

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. The proteasome: a suitable antineoplastic target;Adams;Nat Rev Cancer,2004

2. The proteasome: a novel target for cancer chemotherapy;Almond;Leukemia,2002

3. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132;Crawford;Cancer Res,2006

4. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells;Hideshima;Cancer Res,2002

5. The proteasome: a worthwhile target for the treatment of solid tumors?;Milano;Eur J Cancer,2007

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation;Molecular Therapy: Oncology;2024-06

2. Molecular characterization of ANKRD1 in rhabdomyosarcoma cell lines: expression, localization, and proteasomal degradation;Histochemistry and Cell Biology;2024-02-23

3. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes;EMBO Molecular Medicine;2022-08-02

4. Comprehensive Profiling Reveals Prognostic and Immunogenic Characteristics of Necroptosis in Soft Tissue Sarcomas;Frontiers in Immunology;2022-05-18

5. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes;2022-01-04